Breaking News Instant updates and real-time market news.

RHHBY

Roche

$31.33

0.39 (1.26%)

06:23
12/07/17
12/07
06:23
12/07/17
06:23

Roche's Hemlibra every four weeks controlled bleeds in Phase III study

Roche announced interim results from the phase III HAVEN 4 study evaluating Hemlibra prophylaxis dosed once every four weeks in adults and adolescents with haemophilia A with and without inhibitors to factor VIII. At this interim analysis after a median of 17 weeks of treatment, Hemlibra prophylaxis showed a clinically meaningful control of bleeding. These results are consistent with previous studies of Hemlibra dosed once weekly or every two weeks, including the pivotal studies in haemophilia A with inhibitors, HAVEN 1 in adults and adolescents and HAVEN 2 in children, as well as the phase III HAVEN 3 study in adults and adolescents with haemophilia A without inhibitors. The most common adverse events with Hemlibra were injection site reactions, with no new safety signals observed. No thrombotic microangiopathy or thrombotic events occurred in this study. Data from the HAVEN 4 study will be presented at an upcoming medical meeting and submitted to health authorities around the world for approval consideration. These results add to the growing body of evidence supporting that Hemlibra may benefit all people with haemophilia A regardless of inhibitor status, while providing flexible and less burdensome administration options.

  • 07

    Dec

  • 23

    Dec

  • 23

    Feb

RHHBY Roche
$31.33

0.39 (1.26%)

11/20/17
DBAB
11/20/17
NO CHANGE
Target $53
DBAB
Hold
Deutsche cuts Bioverativ target to $53 after positive Roche data
Deutsche Bank analyst Andrew Peters lowered his price target for Bioverativ (BIVV) to $53 from $65 and remains cautious on the shares following today's positive data from Roche's (RHHBY) Phase 3 study evaluating Hemlibra in noninhibitor hemophilia A patients. While full data is needed to better understand the clinical and competitive profile, the data reported today suggest Hemlibra will likely pressure the longevity and sustainability of Bioverativ's Eloctate franchise, Peters told investors earlier in a research note. The analyst reiterated a Hold rating on Bioverativ shares. The stock closed the trading day down 9.5% to $50.76. Shire (SHPG), another company with a hemophilia franchise, closed today down 4% to $141.37 while Roche rallied 6% to $30.82.
11/22/17
COWN
11/22/17
NO CHANGE
Target $105
COWN
Outperform
Impressive Venclexta abstract positive for AbbVie, says Cowen
Cowen analyst Steven Scala said a late breaking ASH abstract showed impressive data for AbbVie's Venclexta drug used in chronic lymphocytic leukemia. The analyst has modeled $2.6N in sales in 2024 and company guidance suggests sales could reach $6B in 2025. Scala reiterated his Outperform rating and $105 price target on AbbVie shares.
12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.
12/07/17
JPMS
12/07/17
NO CHANGE
JPMS
Overweight
Roche to outperform on 'very strong' lung cancer data, says JPMorgan
JPMorgan analyst Richard Vosser says Roche reported "very strong" detailed progression free survival data from its IMPower150 lung cancer study. At the conference later today, the analyst expects to see strong interim overall survival data. He expects the shares to outperform by 1%-2% following this morning's data. Vosser has an Overweight rating on Roche.

TODAY'S FREE FLY STORIES

01:45
08/16/18
08/16
01:45
08/16/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

AVLR

Avalara

$34.68

-1.375 (-3.81%)

23:51
08/15/18
08/15
23:51
08/15/18
23:51
Upgrade
Avalara rating change at Goldman Sachs »

Avalara upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLNX

Xilinx

$70.61

-0.56 (-0.79%)

23:22
08/15/18
08/15
23:22
08/15/18
23:22
Hot Stocks
SK Telecom deploys Xilinx FPGAs for AI acceleration »

Xilinx jointly announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IVC

Invacare

$16.50

0.15 (0.92%)

21:30
08/15/18
08/15
21:30
08/15/18
21:30
Downgrade
Invacare rating change at KeyBanc »

Invacare downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

PRO

Pros Holdings

$35.39

-1.91 (-5.12%)

20:39
08/15/18
08/15
20:39
08/15/18
20:39
Syndicate
Pros Holdings 3.8M share Secondary priced at $34.00 »

It appears selling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 21

    Aug

  • 06

    Sep

  • 07

    Sep

  • 16

    Aug

IIN

IntriCon

$63.85

-4.9 (-7.13%)

20:34
08/15/18
08/15
20:34
08/15/18
20:34
Syndicate
IntriCon 1.5M share Secondary priced at $55.00 »

Stifel acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 16

    Aug

ADUS

Addus HomeCare

$59.35

-3.1 (-4.96%)

20:33
08/15/18
08/15
20:33
08/15/18
20:33
Syndicate
Addus HomeCare 2.1M share Secondary priced at $59.00 »

Jefferies, RBC Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

LABL

Multi-Color

$63.90

-1 (-1.54%)

20:32
08/15/18
08/15
20:32
08/15/18
20:32
Downgrade
Multi-Color rating change at KeyBanc »

Multi-Color downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$90.24

-0.565 (-0.62%)

, JCP

J.C. Penney

$2.40

-0.24 (-9.09%)

20:25
08/15/18
08/15
20:25
08/15/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

WMT

Walmart

$90.24

-0.565 (-0.62%)

JCP

J.C. Penney

$2.40

-0.24 (-9.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 16

    Aug

WUBA

58.com

$58.59

-3.27 (-5.29%)

19:09
08/15/18
08/15
19:09
08/15/18
19:09
Hot Stocks
Breaking Hot Stocks news story on 58.com »

58.com sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 10

    Sep

WUBA

58.com

$58.59

-3.27 (-5.29%)

19:08
08/15/18
08/15
19:08
08/15/18
19:08
Earnings
58.com reports Q2 adjusted earnings per ADS 82c, consensus 68c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

  • 10

    Sep

WAIR

Wesco Aircraft

$13.65

-0.3 (-2.15%)

19:07
08/15/18
08/15
19:07
08/15/18
19:07
Initiation
Wesco Aircraft initiated at UBS »

Wesco Aircraft initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGI

Triumph Group

$21.10

-0.9 (-4.09%)

19:07
08/15/18
08/15
19:07
08/15/18
19:07
Initiation
Triumph Group initiated at UBS »

Triumph Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HXL

Hexcel

$68.40

-1.13 (-1.63%)

19:06
08/15/18
08/15
19:06
08/15/18
19:06
Initiation
Hexcel initiated at UBS »

Hexcel initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

ERJ

Embraer

$18.64

-0.495 (-2.59%)

19:05
08/15/18
08/15
19:05
08/15/18
19:05
Initiation
Embraer initiated at UBS »

Embraer initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CW

Curtiss-Wright

$130.92

-2.42 (-1.81%)

19:04
08/15/18
08/15
19:04
08/15/18
19:04
Initiation
Curtiss-Wright initiated at UBS »

Curtiss-Wright initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLL

L3 Technologies

$208.08

-1.73 (-0.82%)

19:03
08/15/18
08/15
19:03
08/15/18
19:03
Initiation
L3 Technologies initiated at UBS »

L3 Technologies initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$192.29

-1.33 (-0.69%)

19:03
08/15/18
08/15
19:03
08/15/18
19:03
Initiation
General Dynamics initiated at UBS »

General Dynamics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDRBF

Bombardier

$0.00

(0.00%)

19:02
08/15/18
08/15
19:02
08/15/18
19:02
Initiation
Bombardier initiated at UBS »

Bombardier initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEI

Heico

$76.50

-1.81 (-2.31%)

19:00
08/15/18
08/15
19:00
08/15/18
19:00
Initiation
Heico initiated at UBS »

Heico initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 13

    Sep

  • 06

    Nov

HRS

Harris

$162.73

-2.15 (-1.30%)

18:59
08/15/18
08/15
18:59
08/15/18
18:59
Initiation
Harris initiated at UBS »

Harris initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$291.52

-2.35 (-0.80%)

18:59
08/15/18
08/15
18:59
08/15/18
18:59
Initiation
Northrop Grumman initiated at UBS »

Northrop Grumman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNC

PNC Financial

$142.03

-0.7 (-0.49%)

, WFC

Wells Fargo

$57.99

-0.08 (-0.14%)

18:57
08/15/18
08/15
18:57
08/15/18
18:57
Periodicals
PNC faces subpoenas over low-income housing tax credits, Bloomberg says »

PNC Financial (PNC) has…

PNC

PNC Financial

$142.03

-0.7 (-0.49%)

WFC

Wells Fargo

$57.99

-0.08 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

  • 12

    Apr

  • 13

    Jul

  • 15

    Oct

UTX

United Technologies

$131.75

-0.65 (-0.49%)

18:57
08/15/18
08/15
18:57
08/15/18
18:57
Initiation
United Technologies initiated at UBS »

United Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

B

Barnes Group

$65.59

-0.26 (-0.39%)

18:56
08/15/18
08/15
18:56
08/15/18
18:56
Initiation
Barnes Group initiated at UBS »

Barnes Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.